The Glass is Half Full Thread., page-33

Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by Janssen.

Is this the path Biotron may take. Especially considering the boards links to J&J. Not entering biotech showcase which they have for the past 10 years. Stephen coming on board as advisor I assume as this is his role with most other companies he is a part of. No update for nearly 6 months after reporting data from phase 2 trial. Is something actually in the works???